37 results about "L-Pyroglutamic Acid" patented technology

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

The application discloses derivatives of pyroglutamic acid-tetrapeptide-7 and application thereof. The derivatives of pyroglutamic acid-tetrapeptide-7 or pharmaceutically acceptable salts thereof have the following structure: the substituent R is selected from the group consisting of. The derivatives of pyroglutamic acid-tetrapeptide-7 have excellent effects of anti-inflammation, promoting synthesis of collagen and / or elastin, reducing wrinkle area or wrinkle degree, and have a smaller effective concentration compared with tetrapeptide-7, and can be applied to medicines, cosmetics or skin care products as main active ingredients.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to clofazimine-organic acid co-crystals, a preparation method and application thereof. The clofazimine-organic acid co-crystal is one of clofazimine-ferulic acid monohydrate co-crystal, clofazimine-ferulic acid co-crystal, clofazimine-glutaric acid co-crystal, clofazimine-glycolic acid co-crystal (CFZ-GA 1:1), clofazimine-glycolic acid co-crystal (CFZ-GA 1:1.5), clofazimine-salicylic acid co-crystal, clofazimine-L-aspartic acid co-crystal, clofazimine-L-pyroglutamic acid co-crystal, clofazimine-gallic acid co-crystal, clofazimine-succinic acid co-crystal, clofazimine-tartaric acid co-crystal and clofazimine-DL-mandelic acid co-crystal. The clofazimine-organic acid co-crystal provided by the application significantly improves the solubility and fluidity of clofazimine, thereby improving the bioavailability of clofazimine, and has a broad medicinal prospect.

The present disclosure encompasses solid state forms of Lucerastat, in embodiments crystalline Lucerastat: L-Pyroglutamic acid, crystalline Lucerastat: Salicylic acid, crystalline Lucerastat: Fumaric acid, crystalline Lucerastat: Benzoic acid and crystalline Lucerastat: o-Acetylsalicylic acid, solid state form thereof, processes for preparation thereof, and pharmaceutical compositions thereof.

To provide a technology for suppressing unpleasant sourness that occurs in a food composition containing acetic acid when stored for a long period of time. [Solution] A food composition that satisfies the following requirements (i) and (ii). (i) The acetic acid content is 3.0% by mass or more. (ii) The ratio of the pyroglutamic acid content (ppm by mass) to the acetic acid content (% by mass) is 70 or less.

The processed food product has a xanthine / pyroglutamic acid ratio between the xanthine content (units: μg / g) and the pyroglutamic acid content (units: μg / g) of 0.0200 or less and a pyroglutamic acid content of 40 μg / g or greater. The processed food contains at least one component (X) selected from the group consisting of a protein having had xanthine oxidase activity and a component derived from the protein.

The application provides a pyroglutamic acid transaminase mutant and application thereof, the mutant is obtained by mutation on the basis of wild-type pyroglutamic acid transaminase, and specific mutation includes at least one of the following sites: (1) the 13th isoleucine is mutated into arginine; (2) the 35th valine is mutated into arginine; (3) the 183rd asparagine is mutated into aspartic acid; and the mutant is suitable for industrial enzymatic production of L-aspartic acid and the process of amino acids taking L-aspartic acid as a precursor; especially, the I13R / V35R / N183D mutant obtained by modification has high positive catalytic activity and strict direction selectivity, and completely loses the reverse reaction activity of decomposing L-aspartic acid; the mutant is overexpressed with phosphoenolpyruvate carboxylase in L-threonine production strain THRS-6, and a high-efficiency L-threonine synthesis metabolic pathway is constructed, and the yield of L-threonine is significantly improved when glucose is used as a substrate.

The invention relates to the field of medicinal chemistry, in particular to a preparation method of L-pyroglutamic acid etogliflozin. An ethyl acetate / water system is adopted to dissolve an L-pyroglutamic acid etogliflozin crude product, after filtration, n-heptane is added, cooling and crystallization are performed to obtain the L-pyroglutamic acid etogliflozin, in the prepared product, the ratio of the etogliflozin to the L-pyroglutamic acid eutectic crystal is stable, the residual amount of a solvent is low, the content of an impurity Y can be controlled to be 0.05% or below, the minimum content can be controlled to be 0.02%, the product purity is high, and the yield is high. The yield is high. The method is low in production cost, simple to operate, high in yield, high in product purity, stable in quality and suitable for industrial production.

Disclosed are antibodies or antigen-binding fragments thereof that bind to AβpE3, an N-terminally truncated, pyroglutamic acid-modified form of amyloid beta (Aβ), and their therapeutic and diagnostic uses.

The application relates to the technical field of composite boards, and particularly discloses an anti-deformation environment-friendly composite board and a production process thereof. The composite board is made of amino-siloxane modified bamboo fibers, pyroglutamic acid-polyethylene glycol ester and poly-lactic acid which are mixed and then hot-pressed, secondarily compressed and shaped. The used materials have good degradability and reusability, meet the green environmental protection concept, have good stability and impact resistance, and can meet the demands of most users.

The invention discloses a metabolic marker for diagnosing lung function grading in a stable phase of chronic obstructive pulmonary disease and application of the metabolic marker. According to the invention, in a training set, the lysophosphatidylcholine (17: 0 / 0: 0) is combined with the dimethylglycine or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0), the dimethylglycine is combined with the 5-hydroxyindoleacetic acid or the lysophosphatidylcholine (17: 0 / 0: 0), and the dimethylglycine is combined with the L-pyroglutamic acid or the lysophosphatidylcholine (17: 0 / 0: 0). The combination of the L-pyroglutamic acid and the 5-hydroxyindoleacetic acid has excellent diagnosis efficiency in diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the chronic obstructive pulmonary disease in the stable phase; further, verification results in a verification set show that the four combined metabolic markers have excellent accuracy in combined diagnosis and distinguishing of patients with the lung functions of the chronic obstructive pulmonary disease at the 1-2 level and the 3-4 level in the stable phase. Therefore, the four combined metabolic markers have the prospect of being developed into a kit for diagnosing and distinguishing lung function 1-2 level and 3-4 level patients of the stable-phase chronic obstructive pulmonary disease.

The invention discloses an aqueous zinc metal battery electrolyte and a zinc metal battery, and belongs to the technical field of batteries, the aqueous zinc metal battery electrolyte comprises L-pyroglutamic acid, zinc salt and water, and the concentration of the L-pyroglutamic acid in the aqueous zinc metal battery electrolyte is 0.01-0.5 mol / L. According to the water-based zinc metal battery electrolyte disclosed by the invention, the L-pyroglutamic acid with a specific concentration is added, and after the L-pyroglutamic acid is introduced into the water-based zinc metal battery electrolyte, the L-pyroglutamic acid has the functions of reconstructing a hydrogen bond network and creating a strong acid environment; the three problems of hydrogen evolution side reaction, corrosion reaction and zinc dendrite growth at a zinc negative electrode-electrolyte interface can be solved, and the specific capacity, coulombic efficiency and cycle life of the zinc metal battery are effectively improved.

The present application relates to the biomedical technology field, and particularly to a blood biomarker for early coronary heart disease diagnosis, and a screening method and application thereof.The blood biomarker comprises blood clinical indicators and plasma metabolome characteristics, the blood clinical indicators comprise direct bilirubin, aspartate aminotransferase and high-density lipoprotein, and the plasma metabolome characteristics comprise pyroglutamic acid, N-formyl-L-methionine, hypoxanthine, pinobetsin and L-valyl-alanine.The present application not only uses plasma metabolome characteristics, but also incorporates blood clinical indicators through blood routine and blood biochemical detection, compared with other methods, more comprehensively reflects the physiological and pathological state of the body, reduces the possibility of result deviation, and therefore adopts multi-dimensional blood biomarkers, which can more accurately predict the risk of early coronary heart disease.In addition, the adoption of multi-dimensional blood biomarkers can also improve the specificity and sensitivity of screening and diagnosis of early coronary heart disease.

The present invention provides a tegoprazan injection and a preparation method therefor. The injection comprises tegoprazan, pyroglutamic acid, a co-solvent, and water for injection. The preparation thereof comprises the following steps: formulating pyroglutamic acid into a pyroglutamic acid solution with a certain concentration by using water for injection; and adding tegoprazan to a co-solvent, then adding the pyroglutamic acid solution for dissolution, and performing filtration, pouring, filling with nitrogen, sealing, and sterilization. The product obtained in the present invention has good clarity and stability. The preparation method has a low production cost, a simple process flow, and strong operability, and is suitable for large-scale industrial production.

The application provides a method for recovering pyroglutamic acid from glutamic acid fermentation liquor, which comprises the following steps: removing bacteria bodies from the glutamic acid fermentation liquor through centrifugation; extracting glutamic acid from the supernatant through isoelectric separation after concentration; separating ammonium sulfate from the glutamic acid isoelectric mother liquor through concentration and crystallization; separating through electrodialysis after decolorization and filtration of the secondary mother liquor; collecting concentrated water and dilute water respectively; recycling the dilute water to the isoelectric separation process; and separating ammonium sulfate and pyroglutamic acid through alcohol extraction and filtration of the concentrated water. The method can reduce production cost and provide a new means for effective recovery and utilization of pyroglutamic acid in the monosodium glutamate industry by treating the glutamic acid isoelectric mother liquor through electrodialysis to recover high-value-added product pyroglutamic acid.

Disclosed in the present invention are a metabolite combination for evaluating the risk of biliary atresia in neonates and a use thereof. The metabolite combination comprises one or more of the following: hyocholic acid, pyroglutamic acid, α-aminobutyric acid, 3-methyl-2-oxovaleric acid and monoconjugated bilirubin, and the metabolite combination cannot only contain one metabolite of monoconjugated bilirubin. The metabolite combination has relatively high correlation with biliary atresia, and has high accuracy, sensitivity and specificity for evaluation of the risk of biliary atresia in neonates.

The invention belongs to the technical field of analytical chemistry, and relates to a method for detecting ion components and related impurities in an electrolyte-containing compound amino acid injection. The ion exclusion chromatography established by the invention can be used for simply and quickly detecting complex components (citric acid, phosphoric acid, lactic acid, N, N-diacetylcystine, acetic acid, sulfurous acid and pyroglutamic acid) in the compound amino acid injection, and the specificity and accuracy of quality control are improved. Data of the embodiment show that the method provided by the invention is high in detection sensitivity, high in separation capacity and simple and rapid to operate, can reduce sample pretreatment links and resin regeneration time, shortens sample treatment and detection time, conforms to the idea of accurate, efficient and green detection, and is suitable for large-scale popularization and application. The method is of great significance to quality control research of compound amino acid injection medicines.

The application discloses a metabolic marker composition for early cervical cancer diagnosis and a screening method and application thereof. The metabolic marker composition for early cervical cancer diagnosis comprises pyroglutamic acid, lysophosphatidylcholine 20:3, phosphatidylcholine 32:2 and pyruvic acid. The metabolic marker composition provided by the application has high sensitivity and specificity when used for early cervical cancer diagnosis, can realize precise screening of early cervical cancer, and provides important help for prevention of cervical cancer and reduction of morbidity. Meanwhile, the metabolic marker composition is simple in operation, convenient in sample acquisition, low in cost, and non-invasive when used for early cervical cancer diagnosis, so that patients can more conveniently, quickly and safely receive detection, and is more suitable for large-scale population screening and regular tracking in areas with tight medical resources.

This invention belongs to the field of biomedical technology, specifically relating to the application of metabolic markers in the preparation of products for diagnosing abdominal aortic aneurysms. The metabolic markers include 5-δ-hydroxybutylhydantoin, 1-α-amino acid, and PGF. 2α The present invention provides one or more of the following metabolites: D-pyroglutamic acid, nicotinic glucuronide, cysteine ​​glutathione disulfide, or Trp-P-1. Experiments have confirmed that the seven metabolites, alone or in combination, have good specificity and sensitivity as metabolic markers for diagnosing abdominal aortic aneurysms.

This invention discloses a method for separating the enantiomers of N-Boc-L-pyroglutamic acid ethyl ester and its application, comprising the following steps: taking a test sample containing the enantiomers of N-Boc-L-pyroglutamic acid ethyl ester, and separating them by liquid chromatography. The liquid chromatography conditions include: using a Daicel AD-H column as the stationary phase, and using a mixed solution containing n-hexane and anhydrous ethanol as the mobile phase for isocratic elution, wherein the volume ratio of n-hexane to anhydrous ethanol in the mobile phase is 3-9:1. The chromatographic conditions of this invention can achieve effective separation of N-Boc-L-pyroglutamic acid ethyl ester and its enantiomers, with a resolution of 9.77 or higher. Furthermore, the short retention time of N-Boc-L-pyroglutamic acid ethyl ester in this invention enables rapid and effective separation, providing technical assurance for controlling the quality of N-Boc-L-pyroglutamic acid ethyl ester.

The present application belongs to the technical field of pesticides, and particularly relates to a kind of fungicide composition for preventing and treating bacterial leaf streak of rice. The fungicide composition for preventing and treating bacterial leaf streak of rice is composed of amino acid and auristatin or paclobutrazol; the mass ratio of the amino acid and auristatin is 1-7:14-1; the mass ratio of the amino acid and paclobutrazol is 1-20:8-1. When L-pyroglutamic acid is used in combination with auristatin or paclobutrazol, the effect of synergism is found, and compared with single active ingredient, the prevention and treatment effect on bacterial leaf streak of rice can be improved, and the new high-efficiency fungicide can be developed. In addition, compared with single active ingredient, the fungicide composition for preventing and treating bacterial leaf streak of rice can reduce the risk of drug resistance, and is safe.

The invention relates to the field of medicines, in particular to an etogliflozin tablet and a preparation method thereof. The etogliflozin tablet disclosed by the invention is prepared from the following components: L-pyroglutamic acid etogliflozin, lactose, microcrystalline cellulose, magnesium stearate and carboxymethyl starch sodium. By optimizing the preparation process, the use of auxiliaries is greatly reduced.

The application belongs to the technical field of cosmetic carriers, and specifically discloses a silk fibroin penetration-promoting nanoparticle, a preparation method, a functional cosmetic carrier and application. The penetration-promoting nanoparticle comprises, from inside to outside, a compact inner core region, a lipid limiting interface region, an ion bridging transition region and a complex hydrated outer layer region. The compact inner core region comprises silk fibroin, polyhydric alcohol and polyhydroxy acid ester; the lipid limiting interface region comprises phospholipid, ceramide, cholesterols and fatty acid ester; the ion bridging transition region comprises bridging components and arginine; and the complex hydrated outer layer region comprises trehalose, hyaluronic acid oligosaccharide, pyroglutamic acid sodium, ectoine and a zwitterionic surface component. The technical solution has good particle stability, penetration-promoting capacity, skin retention capacity and formula adaptability.

The invention discloses a metabolic marker composition for early thyroid cancer detection and application thereof, and relates to the technical field of biomedicine, and the metabolic marker composition for early thyroid cancer detection comprises sphingosine 1-phosphate, L-ornithine, pyroglutamic acid and L-valyl-L-serine. The metabolic marker composition provided by the invention has high sensitivity and high specificity when being used for detecting the early thyroid cancer, and can realize detection and screening of the early thyroid cancer. Meanwhile, when the metabolic marker composition is used for early thyroid cancer detection, operation is easy, sample obtaining is convenient, cost is low, a non-invasive detection mode is adopted, only blood samples need to be collected, safety and reliability are achieved, and patient compliance is high.

The invention relates to the technical field of assisted reproduction, and provides a method for predicting embryo uploidy through blastocyst cavity fluid metabolite and application of the method. According to the method, the embryonic chromosome uploidy condition is predicted by detecting the content of pyroglutamic acid in the blastocyst cavity liquid, and accurate quantitative analysis of the pyroglutamic acid in a trace amount of the blastocyst cavity liquid can be realized by adopting a nano electrospray ionization-mass spectrometry (nanoESI-MS) detection technology. Researches find that the content of pyroglutamic acid in aneuploid blastocyst cavity fluid is obviously higher than that of the aneuploid blastocyst, and ROC curve analysis shows that pyroglutamic acid has certain diagnostic value. The invention further constructs a prediction model based on the content of pyroglutamic acid, training and verification are carried out through a machine learning method, and the result shows that the model can effectively predict embryo uploidy, a new theoretical basis and an intervention target are provided for embryo quality evaluation in an assisted reproduction technology, the success rate and safety of assisted reproduction can be improved, and the method is suitable for popularization and application. And the risk caused by the aneuploid embryo is reduced.

The invention belongs to the technical field of organic chemistry, and discloses a preparation method of crystal copper pyrrolidonecarboxylate, which comprises the following steps: dissolving L-pyroglutamic acid serving as a raw material under an alkaline condition, carrying out complex reaction with copper ions to obtain a copper pyrrolidonecarboxylate reaction solution, carrying out hot filtration and impurity removal on the reaction solution, and concentrating the filtrate to obtain the crystal copper pyrrolidonecarboxylate. Cooling to separate out crystals, filtering, washing and drying to obtain blue-green crystals, namely the copper pyrrolidone carboxylate. The process has the characteristics of high yield, simple post-treatment and the like. The invention provides a novel industrial preparation method which is low in production cost, efficient and environment-friendly.

The invention provides a tigorazan injection and a preparation method thereof. The injection comprises tigorazan, pyroglutamic acid, a cosolvent and water for injection. The preparation method comprises the following steps: preparing pyroglutamic acid into a pyroglutamic acid solution with a certain concentration by using water for injection; the preparation method comprises the following steps: adding tigorazan into a cosolvent, adding a pyroglutamic acid solution for dissolving, filtering, filling, filling nitrogen, sealing and sterilizing. The obtained product is excellent in clarity and stability, and the preparation method is low in production cost, simple in technological process, high in operability and suitable for industrial mass production.

The invention provides a tegorasone pyroglutamate injection and a preparation method thereof. The tegorasone pyroglutamate injection is prepared from an active component tegorasone pyroglutamate and an alcohol solvent. The tigorasone pyroglutamate injection prepared by the invention has high stability, avoids the risk of precipitation of a compatible product in clinical use in a non-aqueous solvent system, and improves the safety of the product in clinical use.

The present application relates to the field of microorganism, especially the application of lactobacillus plantarum TCI378 strain and its metabolite for reducing fat. The present application discloses a metabolite of lactobacillus plantarum, which comprises a compound selected from the group consisting of tryptophyl pyroglutamic acid, 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid, 3-phenyllactic acid (as shown in formula III), or any combination thereof. The present application also discloses the use of the lactobacillus plantarum for preparing a fat-reducing composition or a fat-reducing drug. The lactobacillus plantarum and its metabolite can inhibit the accumulation of fat in fat cells, effectively reduce the content of fat in cells, and achieve the goal of reducing fat and obesity.